Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Credit agrmnt [a]
Director departure
Inv. presentation
Quarterly results
Acq. announced
|
|
PERNIX THERAPEUTICS HOLDINGS, INC. (PTX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 09/25/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 06/26/2019 |
8-K
| Quarterly results |
| 05/21/2019 |
8-K
| Asset disposition |
| 05/14/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/07/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 05/06/2019 |
8-K
| Completion of Acquisition or Disposition of Assets |
| 04/19/2019 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits |
| 04/02/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 04/01/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 02/27/2019 |
8-K
| Quarterly results |
| 02/19/2019 |
8-K
| Quarterly results |
| 02/19/2019 |
GN
| Pernix Therapeutics Holdings, Inc. Enters into Asset Purchase Agreement with Certain Funds Managed by Highbridge Capital Management |
| 02/13/2019 |
SC 13G/A
| RENAISSANCE TECHNOLOGIES LLC reports a 7.9% stake in PERNIX THERAPEUTICS HOLDINGS, INC. |
| 11/21/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 11/13/2018 |
GN
| Detailed Research: Economic Perspectives on Pernix Therapeutics, Hallador Energy, Vince Holding, Tuesday Morning, Information Services Group, and Sienna Biopharmaceuticals — What Drives Growth in Today's Competitive Landscape |
| 11/09/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 11/02/2018 |
GN
| Pernix Therapeutics to Report Third Quarter 2018 Financial Results on Thursday, November 8 |
| 10/31/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/22/2018 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 10/09/2018 |
8-K/A
| Quarterly results |
| 09/12/2018 |
GN
| Pernix Therapeutics Holdings, Inc.'s Subsidiaries File Notice of Appeal in Patent Litigation Concerning Zohydro® ER with BeadTek® |
| 08/27/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 08/27/2018 |
GN
| Pernix Therapeutics Announces Ruling in Patent Litigation Concerning Zohydro® ER with BeadTek® |
| 08/22/2018 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/09/2018 |
10-Q
| Quarterly Report for the period ended June 30, 2018 |
| 08/09/2018 |
8-K
| Quarterly results |
| 08/09/2018 |
GN
| Pernix Therapeutics Reports Second Quarter 2018 Financial Results |
| 08/01/2018 |
SC 13G
| Flynn James E reports a 9.2% stake in Pernix Therapeutics Holdings, Inc. |
| 08/01/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...|
Docs:
|
"Form of Articles Supplementary for 0% Series C Perpetual Convertible Preferred Stock",
"Form of Exchange Agreement, by and among Pernix Therapeutics Holdings, Inc., Deerfield Management L.P. and certain of its affiliates",
"The exchange of approximately $2.7 million aggregate principal amount of Senior Secured Notes by the Exchange Holders for 1,204,739 shares of Common Stock, which includes accrued and unpaid interest on the Senior Secured Notes; and",
"The exchange of approximately $2.7 million aggregate principal amount of Senior Secured Notes by the Exchange Holders for 1,204,739 shares of Common Stock, which includes accrued and unpaid interest on the Senior Secured Notes; and",
"Form of Amendment No. 3 to the ABL Facility, August 1, 2018, by and among Pernix, the guarantors and lenders party thereto and Cantor Fitzgerald Securities, as agent",
"Form of Amendment No. 2 to the Term Facility, by and among PIP DAC, the lenders party thereto and Cantor Fitzgerald Securities, as agent",
"Pernix Therapeutics Announces a Series of Transactions To Strengthen Its Balance Sheet and Improve Financial Flexibility MORRISTOWN, N.J. – August 1, 2018 – Pernix Therapeutics Holdings, Inc. , a specialty pharmaceutical company, announces a series of transactions aimed at strengthening its balance sheet and improving financial flexibility, as described below. Exchange Agreement Pernix entered into exchange agreements with certain holders of Pernix’ s outstanding 12% Senior Secured Notes due 2020 for newly issued shares of common stock and shares of a newly created class of convertible preferred stock, the terms of which are described below . These transactions , are expected to close on August 1, 2018. The Exchange Transactions include:" |
|
| 08/01/2018 |
GN
| Pernix Therapeutics Announces a Series of Transactions to Strengthen Its Balance Sheet and Improve Financial Flexibility |
| 07/31/2018 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 07/31/2018 |
GN
| Pernix Therapeutics to Report Second Quarter 2018 Financial Results on Thursday, August 9 |
| 06/22/2018 |
8-K
| Other Events, Financial Statements and Exhibits |
| 06/22/2018 |
GN
| Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss |
|
|
|